Bristol-Myers Squibb
Company and Pharmaceutical Company
Bristol-Myers Squibb Sees Perfect Timing to Divest Huge Mead Johnson Nutrition Stakeby: The Burrill Report November 26, 2009 | about: BMY / MJN Bristol-Myers Squibb (BMY) will sell its last non-biopharmaceutical holding, a majority stake in Mead Johnson Nutrition (MJN), the company said. The pediatric nutrition company... In this article: Bristol-Myers Squibb and Cash flow |
-
CFO | 1 day ago
No Future Tax Shock for Bristol-Myers
...of the plan, then the Mead-Johnson stock will not constitute "qualified property" with respect to Bristol-Myers, making the distribution of stock to Bristol-Myers taxable.3 However, as we indicated in a prior report (see "Spin-off...
In this article: Tax and Internal Revenue Service
-
AP Online | 3 days ago
Bristol-Myers extends partnership with Asterand
...in Detroit and the United Kingdom, will continue to provide drug discovery services and human tissue and clinical samples to Bristol-Myers Squibb. The tissue and samples will be used in research on potential drugs. The companies entered...
In this article: NEW YORK, Detroit, and United Kingdom
-
Centre Daily Times | 3 days ago
Asterand Announces Extension of Agreement with Bristol-Myers Squibb
...engaged in drug discovery research, today announced that it has extended its collaboration with Bristol-Myers Squibb Company (NYSE: BMY) for access to Asterand's products and services for up to three years. The agreement will focus on...
-
Bristol-Myers splits off Mead Johnson Nutrition
...owns about 83 percent of Mead stock, expects the deal to add to earnings starting in 2010. The company says the stock swap is designed to allow Bristol-Myers shareholders to exchange some, all or none of their shares for Mead stock...
In this article: Bristol-Myers, NEW YORK, Revenue, and Goldman, Sachs & Co.
-
Reuters | November 15, 2009
Bristol Myers to spin off Mead stock
Bristol-Myers Squibb Co <BMY.N> said on Sunday it plans to split off its 83 percent stake in Mead Johnson Nutrition Company <MJN.N> in a deal that lets Bristol shareholders exchange their shares for Mead Johnson common stock. Under terms...
In this article: Bristol Myers, Bristol, and New York Stock Exchange
-
washingtonpost.com | November 15, 2009
Bristol-Myers splits off Mead Johnson Nutrition
In this article: NEW YORK
Trends
Loading...
More on Bristol-Myers Squibb
Description from Wikipedia:
Bristol-Myers Squibb (NYSE: BMY), colloquially referred to as BMS, is a pharmaceutical company. Founded in 1887 by William McLaren Bristol and John Ripley Myers in Clinton, NY (both were graduates of Hamilton College), Bristol-Myers merged with Squibb Corporation in 1989. James M. Cornelius is the New York City-based company's Chairman and CEO.
Bristol-Myers Squibb manufactures prescription pharmaceuticals in several therapeutic areas, including cancer, HIV/AIDS, cardiovascular disease, diabetes, hepatitis, rheumatoid arthritis and psychiatric disorders. It is also the parent company of Mead Johnson Nutrition, which manufactures nutritional products such as Enfamil baby formulas and infant vitamin supplements like Tri-Vi-Sol. Bristol-Myers Squibb has a mission to "Extend and Enhance Human Life" and works to discover and develop medicines in areas of serious unmet medical need.
BMS' primary R&D sites are located in Lawrenceville, New Jersey (formerly Squibb) and Wallingford, Connecticut (formerly Bristol-Myers), with other sites around the US, in Ireland, and in other countries.
A major restructuring has been implemented which involves focusing on the pharmaceutical business and biologic products along with productivity initiatives, cost-cutting and streamlining business operations.
In 2005, BMS was among 53 entities that contributed the maximum of $250,000 to the second inauguration of President George W. Bush.
BMS is a Fortune 500 Company (#129 in 2007 list).
On July 22, 2009, BMS offered to acquire the biotechnology firm, Medarex, for $16 per share.
- Name:
- Bristol-Myers Squibb Company
- Type:
- Public (NYSE: BMY)
- Location:
- New York, New York
- Founded:
- 1887
- Stock Symbol:
- BMY
- Industry:
- Pharmaceuticals
- Key People:
- James Cornelius, CEO
- Revenue:
- US$ 19.98 billion (2008)
- Net Income:
- US$ 2.165 billion (2008)
- No. of Employees:
- 35,000 (2009)
- Market Cap:
- US$ 36.7 billion (Oct. 2008)
Explore everything named Bristol-Myers Squibb...
